"Prostaglandin D2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects.
| Descriptor ID |
D015230
|
| MeSH Number(s) |
D10.251.355.255.550.200.200 D23.469.050.175.725.200.200
|
| Concept/Terms |
Prostaglandin D2- Prostaglandin D2
- D2, Prostaglandin
- 11-Dehydroprostaglandin F2 alpha
- 11 Dehydroprostaglandin F2 alpha
- F2 alpha, 11-Dehydroprostaglandin
- alpha, 11-Dehydroprostaglandin F2
- PGD2
- 11-Dehydroprostaglandin F2alpha
- 11 Dehydroprostaglandin F2alpha
- F2alpha, 11-Dehydroprostaglandin
|
Below are MeSH descriptors whose meaning is more general than "Prostaglandin D2".
Below are MeSH descriptors whose meaning is more specific than "Prostaglandin D2".
This graph shows the total number of publications written about "Prostaglandin D2" by people in this website by year, and whether "Prostaglandin D2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prostaglandin D2" by people in Profiles.
-
Grabocka E, Bar-Sagi D. Mutant KRAS Enhances Tumor Cell Fitness by Upregulating Stress Granules. Cell. 2016 Dec 15; 167(7):1803-1813.e12.
-
Kuriyan AE, Woeller CF, O'Loughlin CW, Phipps RP, Feldon SE. Orbital fibroblasts from thyroid eye disease patients differ in proliferative and adipogenic responses depending on disease subtype. Invest Ophthalmol Vis Sci. 2013 Nov 08; 54(12):7370-7.
-
Kuriyan AE, Lehmann GM, Kulkarni AA, Woeller CF, Feldon SE, Hindman HB, Sime PJ, Huxlin KR, Phipps RP. Electrophilic PPAR? ligands inhibit corneal fibroblast to myofibroblast differentiation in vitro: a potentially novel therapy for corneal scarring. Exp Eye Res. 2012 Jan; 94(1):136-45.
-
Chen Y, Perussia B, Campbell KS. Prostaglandin D2 suppresses human NK cell function via signaling through D prostanoid receptor. J Immunol. 2007 Sep 01; 179(5):2766-73.
-
Han S, Sidell N, Fisher PB, Roman J. Ligands of peroxisome proliferator-activated receptor gamma inhibit lung cancer cell growth and induce apoptosis by stimulation of P21 expression. Chest. 2004 May; 125(5 Suppl):134S.
-
Matsuo T, Matsumura T, Sakai M, Senokuchi T, Yano M, Kiritoshi S, Sonoda K, Kukidome D, Pestell RG, Brownlee M, Nishikawa T, Araki E. 15d-PGJ2 inhibits oxidized LDL-induced macrophage proliferation by inhibition of GM-CSF production via inactivation of NF-kappaB. Biochem Biophys Res Commun. 2004 Feb 13; 314(3):817-23.
-
Skolnik PR, Rabbi MF, Mathys JM, Greenberg AS. Stimulation of peroxisome proliferator-activated receptors alpha and gamma blocks HIV-1 replication and TNFalpha production in acutely infected primary blood cells, chronically infected U1 cells, and alveolar macrophages from HIV-infected subjects. J Acquir Immune Defic Syndr. 2002 Sep 01; 31(1):1-10.
-
Wang C, Fu M, D'Amico M, Albanese C, Zhou JN, Brownlee M, Lisanti MP, Chatterjee VK, Lazar MA, Pestell RG. Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1. Mol Cell Biol. 2001 May; 21(9):3057-70.
-
Kane GC, Tollino M, Pollice M, Kim CJ, Cohn J, Murray JJ, Dworski R, Sheller J, Fish JE, Peters SP. Insights into IgE-mediated lung inflammation derived from a study employing a 5-lipoxygenase inhibitor. Prostaglandins. 1995 Jul; 50(1):1-18.
-
Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell. 1994 Feb 11; 76(3):519-29.